DOCSLIB.ORG

Venous Air Embolism Induces Both Platelet Dysfunction and Thrombocytopenia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Venous Air Embolism Induces Both Platelet Dysfunction and Thrombocytopenia Acta Anaesthesiol Scand 2009; 53: 736–741 r 2009 The Authors Printed in Singapore. All rights reserved Journal compilation r 2009 The Acta Anaesthesiologica Scandinavica Foundation ACTA ANAESTHESIOLOGICA SCANDINAVICA doi: 10.1111/j.1399-6576.2009.01947.x Venous air embolism induces both platelet dysfunction and thrombocytopenia 1 2 2 1 1 S. T. SCHA¨ FER ,A.NEUMANN ,J.LINDEMANN ,K.GO¨ RLINGER and J. PETERS 1Klinik fu¨r Ana¨sthesiologie und Intensivmedizin, Universita¨t Duisburg-Essen and Universita¨tsklinikum Essen, Essen, Germany and 2Universita¨t Duisburg-Essen, Essen, Germany Background: In vitro, air bubbles can induce platelet sphate, arachidonic acid, collagen, and the thromboxan activation and platelet to air bubble binding. We therefore analogue U46619 over the dose range assessed indepen- tested in vivo the hypothesis that venous air embolism dent of thrombocytopenia. (Po0.05 vs. baseline). In con- (VAE)induces(1)plateletdysfunctionand(2)thrombocy- trast, rotational thrombelastometry alone was quite topenia. insensitive in detecting VAE-induced coagulation changes, Methods: Adult swine (60.8 Æ 3.9 kg; n 5 8) were anaesthe- showing only at near lethal air dosages a prolonged clot tized, mechanically ventilated, and placed in a semi-upright formation time following activation with tissue factor, position. Air boli (0.5–80 ml) were injected randomly via an ear contact activator, and during spontaneous coagulation vein, and arterial blood was sampled after cumulative air (Po0.05 vs. baseline). dosages of 0, 80, 160, and 240 ml. Coagulation was assessed by Conclusions: VAE induces both a dose-dependent de- impedance aggregometry, rotational thrombelastometry, whole crease in platelet count and a marked decrease in platelet blood count, plasmatic coagulation variables, and fibrinogen, aggregation, independent of thrombocytopenia (Po0.05 D-dimer, protein C, and antithrombin plasma concentrations, vs. baseline). respectively. Results: VAE induced a 47% decrease in platelet count Accepted for publication 29 January 2009 (303 vs. 160 nl À 1; Po0.001) over the dose range assessed, with haematocrit being unaltered. Furthermore, VAE-im- r 2009 The Authors paired platelet aggregation induced by adenosine dipho- Journal compilation r 2009 The Acta Anaesthesiologica Scandinavica Foundation ENOUS air embolism (VAE) is a frequent and function may increase the risk of intraoperative or Vpotentially fatal complication during neurolo- post-operative bleeding, with potential disastrous gical surgery in the sitting position and may occur sequelae in brain surgery. whenever venous pressure at the site of surgery is Accordingly, we tested the hypothesis that VAE near or below atmospheric pressure.1–3 induces (1) platelet dysfunction and (2) thrombo- Intrapulmonary air following VAE is known to cytopenia. cause damage to the endothelium,4,5 creating gaps between endothelial cells and facilitating pulmon- ary oedema.6 Furthermore, air or VAE induces Methods 7,8 9,10 complement and leads to platelet activation. The experimental protocol was approved by the In vitro, direct platelet to air bubble binding has local animal care committee (TSG-No.: G851/05), 9,11 been described. However, to our knowledge, and animals were treated in accordance with the there have been no studies addressing whether guidelines of the American Physiological Society these effects are of importance for platelet function and the Guide for the Care and Use of Laboratory in vivo and to what extent blood coagulation is Animals (NIH publication 85-23, revised 1996). impaired by VAE. Obviously, impaired platelet Attribution of the work: Klinik fu¨r Ana¨sthesiologie und Intensivme- Animal preparation dizin, Universita¨t Duisburg-Essen, Universita¨tsklinikum Essen, Eight male pigs [weight: 60.8 Æ 3.9 kg standard Hufelandstrae 55, D-45122 Essen, Germany. deviation (SD)] were studied. After an overnight 736 Venous air embolism and platelet dysfunction fast, the animals were pre-anaesthetized with keta- addition of 20 ml Cytochalasin D (FibTEMt,Penta- mine [27 mg/kg intramuscularly (i.m.)], azaperone pharm), and spontaneous coagulation (NaTEMt, (2.2 mg/kg i.m.), and atropine (2 mg i.m.). After Pentapharm) were assessed. Whole blood count, placement of an 18-G peripheral cannula into a left plasmatic coagulation variables (activated partial ear vein and injection of propofol (2 mg/kg), the thromboplastin time, international normalized ratio, animals were endotracheally intubated and me- and thrombin time), and fibrinogen, D-dimer, pro- chanically ventilated (rate: 12 min À 1, tidal volume: tein C, and antithrombin plasma concentrations 8 ml/kg, inspiratory oxygen fraction: 0.5). Anaes- were also measured. thesia was maintained by propofol (7 mg/kg/h) and fentanyl (5 mg/kg/h) intravenously. Experimental protocol For continuous arterial pressure monitoring and After instrumentation, animals were placed in a blood sampling, an 18-G catheter (Vygon GmbH, 451 semi-upright position19 and eight increments Aachen, Germany) was inserted into the of air (0.5, 1, 2, 5, 10, 20, 40, and 80 ml) were right carotid artery, and an 8.5 F sheath (Arrow injected via an ear vein in a randomized order, International Inc., Reading, PA) was inserted into with every air volume being injected twice. Differ- the right jugular vein for placement of a 7.5 F ent amounts of air were used to simulate the pulmonary artery catheter (CritiCath. SP5507 TD clinical setting of VAE, with different volumes of Catheter, Becton Dickinson Inc., Sandy, UT). air often embolizing over time. Following each Additionally, via an 11 F sheath (Arrow Interna- injection, a consecutive air injection was only tional Inc.) in the right jugular vein, a 10 F intra- performed when no more intracardiac air could cardiac echocardiography (ICE) catheter (AcuNav, be visualized by ICE, as described previously.20 Siemens Medical Solutions, Erlangen, Germany) Whenever cardiocirculatory collapse occurred the was placed into the superior vena cava for detec- experiment was terminated. The cumulative tion of VAE. amount of air injected before the last injection inducing cardiocirculatory collapse was defined as ‘near-lethal air dosage’. Measurements Arterial blood for analysis of variables was Platelet function. Platelet function was analysed drawn before air injections and after cumulative using impedance aggregometry (Multiplate, Dyna- air dosages of 80, 160, and 240 ml, respectively. bite Informationssysteme GmbH, Munich, Ger- 12 many). Platelets were activated by adding either Statistics 20 ml adenosine diphosphate (4 mM), arachidonic Data are presented as means Æ standard deviation acid (30 mM), collagen (4 mg), or the thromboxane (SD), unless indicated otherwise. Statistical analy- analogue U46619 (31 mM) to hirudin anticoagulated sis was performed using the SPSS 13.0 Software blood (25 mg/ml), as described previously.12,13 Ag- package (SPSS Inc., Chicago, IL) and the Microsoft gregation was expressed as area under the curve Excel software package (Microsoft Office XP, (AUC) of the aggregation time relationship for Microsoft, Redmond, WA). the first 7 min, as this best reflects platelet aggre- Statistical differences in values between baseline gation.13,14 and those following VAE were analysed by re- peated measures ANOVA for platelet function Whole blood coagulation. Whole blood coagulation analysis (four measurements), and the Wilcoxon’s was measured using rotational thrombelastometry s signed rank test for analysing whole blood coagu- 15–17 (ROTEM , Pentapharm, Munich, Germany), lation (two measurements), respectively. Platelet based on the traditional thrombelastogram as de- aggregation values were also normalized to platelet 18 scribed by Hartert. Citrated blood was used for all count (AUC/ platelet count), so as to eliminate the experiments and coagulation was assessed following effects of thrombocytopenia. An a-error Po0.05 t recalcification using 0.2 M CaCl2 (20 mlStar-TEM , was used to indicate statistical significance. Pentapharm, Munich, Germany). Platelet activation was initiated with either 20 mltissuethromboplastin Results (i.e., tissue factor and phospholipids, ExTEMt, Pentapharm) or partial thromboplastin (i.e., phos- Platelet count pholipids and elagic acid, InTEMt, Pentapharm), VAE decreased the platelet count by 47% (303 vs. respectively. Furthermore, coagulation after the 160 nl À 1; Po0.001) over the dose range assessed 737 S. T. Scha¨fer et al. Fig. 1. Changes in platelet count follow- ing venous air embolism (VAE). Data (means Æ SD) from swine subjected to VAE. VAE induced a dose-dependent de- crease in the platelet count, with the haematocrit being unaltered. *Po0.05 for platelet count vs. initial value. 1Po0.05 for dose-dependent effect in changes of the platelet count. SD, standard deviation. (0–240 ml of air injected), with haematocrit being unaltered (Fig. 1). The average amount of air inducing cardiocirculatory collapse was 4.6 Æ 1.6 ml/kg. Platelet function VAE impaired platelet aggregation independent of thrombocytopenia and over the dose range assessed (Po0.05 for all activations vs. baseline) regardless of whether induced by adenosine dipho- sphate, arachidonic acid, collagen, or the throm- boxan analogue U46619. A cumulative air dose as small as 80 ml was already associated with a decrease in platelet aggregation (Po0.05) when induced by ADP (À 26%), collagen (À 24%), or U46619 (À 64%). In contrast, 160 ml of air was required for a decrease (À 59%) in platelet aggrega- tion observed after stimulation with arachidonic
Load more

Recommended publications
  • Venous Air Embolism, Result- Retrospective Study of Patients with Venous Or Arterial Ing in Prompt Hemodynamic Improvement
    Ⅵ REVIEW ARTICLE David C. Warltier, M.D., Ph.D., Editor Anesthesiology 2007; 106:164–77 Copyright © 2006, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Diagnosis and Treatment of Vascular Air Embolism Marek A. Mirski, M.D., Ph.D.,* Abhijit Vijay Lele, M.D.,† Lunei Fitzsimmons, M.D.,† Thomas J. K. Toung, M.D.‡ exogenously delivered gas) from the operative field or This article has been selected for the Anesthesiology CME Program. After reading the article, go to http://www. other communication with the environment into the asahq.org/journal-cme to take the test and apply for Cate- venous or arterial vasculature, producing systemic ef- gory 1 credit. Complete instructions may be found in the fects. The true incidence of VAE may be never known, CME section at the back of this issue. much depending on the sensitivity of detection methods used during the procedure. In addition, many cases of Vascular air embolism is a potentially life-threatening event VAE are subclinical, resulting in no untoward outcome, that is now encountered routinely in the operating room and and thus go unreported. Historically, VAE is most often other patient care areas. The circumstances under which phy- associated with sitting position craniotomies (posterior sicians and nurses may encounter air embolism are no longer fossa). Although this surgical technique is a high-risk limited to neurosurgical procedures conducted in the “sitting procedure for air embolism, other recently described position” and occur in such diverse areas as the interventional radiology suite or laparoscopic surgical center. Advances in circumstances during both medical and surgical thera- monitoring devices coupled with an understanding of the peutics have further increased concern about this ad- pathophysiology of vascular air embolism will enable the phy- verse event.
    [Show full text]
  • Pulmonary Embolism a Pulmonary Embolism Occurs When a Blood Clot Moves Through the Bloodstream and Becomes Lodged in a Blood Vessel in the Lungs
    Pulmonary Embolism A pulmonary embolism occurs when a blood clot moves through the bloodstream and becomes lodged in a blood vessel in the lungs. This can make it hard for blood to pass through the lungs to get oxygen. Diagnosing a pulmonary embolism can be difficult because half of patients with a clot in the lungs have no symptoms. Others may experience shortness of breath, chest pain, dizziness, and possibly swelling in the legs. If you have a pulmonary embolism, you need medical treatment right away to prevent a blood clot from blocking blood flow to the lungs and heart. Your doctor can confirm the presence of a pulmonary embolism with CT angiography, or a ventilation perfusion (V/Q) lung scan. Treatment typically includes medications to thin the blood or placement of a filter to prevent the movement of additional blood clots to the lungs. Rarely, drugs are used to dissolve the clot or a catheter-based procedure is done to remove or treat the clot directly. What is a pulmonary embolism? Blood can change from a free flowing fluid to a semi-solid gel (called a blood clot or thrombus) in a process known as coagulation. Coagulation is a normal process and necessary to stop bleeding and retain blood within the body's vessels if they are cut or injured. However, in some situations blood can abnormally clot (called a thrombosis) within the vessels of the body. In a condition called deep vein thrombosis, clots form in the deep veins of the body, usually in the legs. A blood clot that breaks free and travels through a blood vessel is called an embolism.
    [Show full text]
  • Pulmonary Embolism in the First Trimester of Pregnancy
    Obstetrics & Gynecology International Journal Case Report Open Access Pulmonary embolism in the first trimester of pregnancy Summary Volume 11 Issue 1 - 2020 Pulmonary embolism in the first trimester of pregnancy without a known medical history Orfanoudaki Irene M is a very rare complication, which if it is misdiagnosed and left untreated leads to sudden Obstetric Gynecology, University of Crete, Greece pregnancy-related death. The sings and symptoms in this trimester are no specific. The causes for pulmonary embolism are multifactorial but in the first trimester of pregnancy, Correspondence: Orfanoudaki Irene M, Obstetric the most important causes are hereditary factors. Many times the pregnant woman ignores Gynecology, University of Crete, Greece, 22 Archiepiskopou her familiar hereditary history and her hemostatic system is progressively activated for the Makariou Str, 71202, Heraklion, Crete, Greece, Tel +30 hemostatic challenge of pregnancy and delivery. The hemostatic changes produce enhance 6945268822, +302810268822, Email coagulation and formation of micro-thrombi or thrombi and prompt diagnosis is crucial to prevent and treat pulmonary embolism saving the lives of a pregnant woman and her fetus. Received: January 19, 2020 | Published: January 28, 2020 Keywords: pregnancy, pulmonary embolism, mortality, diagnosis, risk factors, arterial blood gases, electrocardiogram, ventilation perfusion scan, computed tomography pulmonary angiogram, magnetic resonanance, compression ultrasonography, echocardiogram, D-dimers, troponin, brain
    [Show full text]
  • Pulmonary Embolism
    Pulmonary Embolism Pulmonary Embolism (PE) is the blockage of one or more arteries in the lungs, ultimately eliminating the oxygen supply causing heart failure. This can take place when a blood clot from another area of the body, most often from the legs, breaks free, enters the blood stream and gets trapped in the lung's arteries. Once a clot is lodged in the artery of the lung, the tissue is then starved of fuel and may die (pulmonary infarct) or the blockage of blood flow may result in increased strain on the right side of the heart. It is estimated that approximately 600,000 patients suffer from pulmonary embolism each year in the US. Of these 600,000, 1/3 will die as a result. Deep Vein Thrombosis (DVT) is the most common precursor of pulmonary embolism. With early treatment of DVT, patients can reduce their chances of developing a life threatening pulmonary embolism to less than one percent. Early treatment with blood thinners is important to prevent a life-threatening pulmonary embolism, but does not treat the existing clot in the leg. Get more information on Deep Vein Thrombosis. Symptoms of PE Symptoms of pulmonary embolism can include shortness of breath; rapid pulse; sweating; sharp chest pain; bloody sputum (coughing up blood); and fainting. These symptoms are frequently nonspecific to pulmonary embolism and can mimic other cardiopulmonary events. Since pulmonary embolism can be life-threatening, if any of these symptoms are present please see your physician immediately. Treatments for PE Anticoagulation The first line of defense when treating pulmonary embolism is by using an anticoagulant.
    [Show full text]
  • Status Epilepticus Due to Cerebral Air Embolism After the Valsalva Maneuver CASE REPORT
    eISSN 2508-1349 J Neurocrit Care 2019;12(1):51-54 https://doi.org/10.18700/jnc.190075 Status epilepticus due to cerebral air embolism after the Valsalva maneuver CASE REPORT Hyun Ji Lyou, MD; Hye Jeong Lee, MD; Grace Yoojin Lee, MD; Received: March 11, 2019 Won-Joo Kim, MD, PhD Revised: May 3, 2019 Accepted: May 27, 2019 Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea Corresponding Author: Won-Joo Kim, MD Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 06273, Republic of Korea Tel: +82-2-2019-3324 Fax: +82-2-3462-5904 E-mail: [email protected] Background: Cerebral air embolism is uncommon but potentially causes catastrophic events such as cardiac damage or even death. However, due to a low overall incidence, it may go undiagnosed. Case Report: A 56-year-old man with a medical history of right upper lobectomy due to lung cancer showed changes in mental status after the Valsalva maneuver, followed by status epilepticus during admission. Brain and chest computed tomography showed cerebral air embolism and accidental pneumothorax in the right major fissure. After antiepileptic drug infusion and oxygen therapy, he recov- ered completely. Conclusion: Since cerebral air embolism may result in fatal outcomes, it should be suspected in patients with sudden neurological de- terioration after routine medical procedures. Keywords: Status epilepticus; Embolism, air; Pneumothorax; Valsalva maneuver INTRODUCTION CASE REPORT Cerebral air embolism is a rare but potentially severe complication A 56-year-old man with a medical history of right upper lobectomy of iatrogenic procedures or destructive lung disease, possibly re- due to lung cancer presented to the emergency room with changes sulting in neurological disorders such as encephalopathy, stroke, or in mental status after the Valsalva maneuver during a pulmonary seizure.
    [Show full text]
  • Hypercoagulability in Hereditary Hemorrhagic Telangiectasia With
    Published online: 2019-09-26 Case Report Hypercoagulability in hereditary hemorrhagic telangiectasia with epilepsy Josef Finsterer, Ernst Sehnal1 Departments of Neurological and 1Cardiology and Intensive Care Medicine, General Hospital Rudolfstiftung, Vienna, Austria, Europe ABSTRACT Recent data indicate that in patients with hereditary hemorrhagic teleangiectasia (HHT), low iron levels due to inadequate replacement after hemorrhagic iron losses are associated with elevated factor‑VIII plasma levels and consecutively increased risk of venous thrombo‑embolism. Here, we report a patient with HHT, low iron levels, elevated factor‑VIII, and recurrent venous thrombo‑embolism. A 64‑year‑old multimorbid Serbian gipsy was diagnosed with HHT at age 62 years. He had a history of recurrent epistaxis, teleangiectasias on the lips, renal and pulmonary arterio‑venous malformations, and a family history positive for HHT. He had experienced recurrent venous thrombosis (mesenteric vein thrombosis, portal venous thrombosis, deep venous thrombosis), insufficiently treated with phenprocoumon during 16 months and gastro‑intestinal bleeding. Blood tests revealed sideropenia and elevated plasma levels of coagulation factor‑VIII. His history was positive for diabetes, arterial hypertension, hyperlipidemia, smoking, cerebral abscess, recurrent ischemic stroke, recurrent ileus, peripheral arterial occluding disease, polyneuropathy, mild renal insufficiency, and epilepsy. Following recent findings, hypercoagulability was attributed to the sideropenia‑induced elevation
    [Show full text]
  • You Have a Pulmonary Embolism (PE)
    YOU HAVE A PE PULMONARY EMBOLISM PATIENT INFORMATION SHEET WHAT IS PE? • A PE is a blood clot that most commonly starts in a vein and then moves into the lung. WHY ARE PEs IMPORTANT? WHAT CAN CAUSE A PE? • They can cause short term and long-term PE usually comes from a DVT of the leg (the risk breathing problems. factors are the same for both). • They can sometimes cause death. Immobility WHAT ARE SYMPTOMS OF PE? • Being in bed for a few days or more • Cast on the leg, not able to stand or walk • Shortness of breath • Air travel for 6 or more hours • Chest pain Injury to blood vessels • Less commonly – feeling faint or passing out, coughing up blood, upper back pain • Broken bones, accidents • A rapid heartbeat • Major surgery • Be aware of symptoms of blood clots in the “Hypercoagulability” (tendency to clot) legs, called deep vein thrombosis (DVT): • Medical conditions (such as cancer) • Swelling – usually of one leg • Hormones (estrogen, pregnancy) • Pain in the calf, inner thigh or groin • Genetic risk factors/family history of DVT/PE • Redness and warmth of the affected leg Ask your doctor about other risk factors. TREATMENT • PE is treated with anticoagulants (“blood • Treatment is sometimes long term thinners”) • Main side effect is bleeding: • Usually pills, but you may start on injections first • Minor (nose/gum bleeds, bruising) • How long you are on treatment will depend on • Major (coughing blood, blood in vomit, urine your risk of having another blood clot and your or stool [may appear as bright red blood or risk of bleeding, but is usually at least 3 months black / tarry stool]) TAKE AWAY MESSAGE • PE is serious and can lead to life threatening complications • Anticoagulant treatment should be taken regularly the way your doctor tells you (refer to the Thrombosis Canada website) • Tell your doctor if you have new symptoms of a blood clot or major bleeding 128 HALLS RD, WHITBY, ON, L1P 1Y8 DOWNLOAD OUR APP FOLLOW US ON TEL | 647-528-8586 EMAIL | [email protected] WEB | www.ThrombosisCanada.ca @THROMBOSISCAN.
    [Show full text]
  • Real-World Data from the Gemelli Hospital HHT Registry
    Journal of Clinical Medicine Article Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia: Real-World Data from the Gemelli Hospital HHT Registry Eleonora Gaetani 1,2,*, Fabiana Agostini 1,2, Igor Giarretta 1,2 , Angelo Porfidia 1,3 , Luigi Di Martino 1,2, Antonio Gasbarrini 1,2, Roberto Pola 1,4 1, and on behalf of the Multidisciplinary Gemelli Hospital Group for HHT y 1 Multidisciplinary Gemelli Hospital Group for HHT, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, 00168 Rome, Italy; [email protected] (F.A.); [email protected] (I.G.); angelo.porfi[email protected] (A.P.); [email protected] (L.D.M.); [email protected] (A.G.); [email protected] (R.P.) 2 Department of Translational Medicine and Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, 00168 Rome, Italy 3 Division of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, 00168 Rome, Italy 4 Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, 00168 Rome, Italy * Correspondence: [email protected]; Tel.: +39-06-30157075 Multidisciplinary Gemelli Hospital Group for HHT: Giulio C. Passali, Maria E. Riccioni, Annalisa Tortora, y Veronica Ojetti, Daniela Feliciani, Leonardo Stella, Clara De Simone, Luigi Corina, Alfredo Puca, Carmelo L. Sturiale, Laura Riccardi, Aldobrando Broccolini, Carmine Di StasiAndrea Contegiacomo, Annemilia Del Ciello, Pietro M. Ferraro, Emanuela Lucci-Cordisco, Giuseppe Zampino, Valentina Giorgio, Giuseppe Marrone, Gabriele Spoletini, Gabriella Locorotondo, Gaetano Lanza, Erica De Candia, Elisabetta Peppucci, Marianna Mazza, Giuseppe Marano, Maria T. Lombardi, Maria G.
    [Show full text]
  • Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism
    ASE GUIDELINES AND STANDARDS Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism Muhamed Saric, MD, PhD, FASE, Chair, Alicia C. Armour, MA, BS, RDCS, FASE, M. Samir Arnaout, MD, Farooq A. Chaudhry, MD, FASE, Richard A. Grimm, DO, FASE, Itzhak Kronzon, MD, FASE, Bruce F. Landeck, II, MD, FASE, Kameswari Maganti, MD, FASE, Hector I. Michelena, MD, FASE, and Kirsten Tolstrup, MD, FASE, New York, New York; Durham, North Carolina; Beirut, Lebanon; Cleveland, Ohio; Aurora, Colorado; Chicago, Illinois; Rochester, Minnesota; and Albuquerque, New Mexico Embolism from the heart or the thoracic aorta often leads to clinically significant morbidity and mortality due to transient ischemic attack, stroke or occlusion of peripheral arteries. Transthoracic and transesophageal echo- cardiography are the key diagnostic modalities for evaluation, diagnosis, and management of stroke, systemic and pulmonary embolism. This document provides comprehensive American Society of Echocardiography guidelines on the use of echocardiography for evaluation of cardiac sources of embolism. It describes general mechanisms of stroke and systemic embolism; the specific role of cardiac and aortic sour- ces in stroke, and systemic and pulmonary embolism; the role of echocardiography in evaluation, diagnosis, and management of cardiac and aortic sources of emboli including the incremental value of contrast and 3D echocardiography; and a brief description of alternative imaging techniques and their role in the evaluation of cardiac sources of emboli. Specific guidelines are provided for each category of embolic sources including the left atrium and left atrial appendage, left ventricle, heart valves, cardiac tumors, and thoracic aorta. In addition, there are recommen- dation regarding pulmonary embolism, and embolism related to cardiovascular surgery and percutaneous procedures.
    [Show full text]
  • Spontaneous Chylothorax Following Septic Pulmonary Embolization
    Hindawi Case Reports in Pulmonology Volume 2020, Article ID 3979507, 3 pages https://doi.org/10.1155/2020/3979507 Case Report Spontaneous Chylothorax following Septic Pulmonary Embolization Michael Agustin , Michele Yamamoto, Chawat Tongma, Leslie Anne Chua, Michael Torres, and Scott Shay Guam Regional Medical City, 133 Route 3, Dededo Guam, USA 96929 Correspondence should be addressed to Michael Agustin; [email protected] Received 30 October 2019; Revised 19 January 2020; Accepted 12 February 2020; Published 22 February 2020 Academic Editor: Nobuyuki Koyama Copyright © 2020 Michael Agustin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Chylothorax is the occurrence of chyle (lymph) in the pleural cavity secondary to damage of the thoracic duct. It is a rare form of pleural effusion which appears as a milky white turbid fluid. Malignancy is the leading cause of nontraumatic chylothorax while inadvertent surgical injury to the thoracic duct is the major cause of traumatic chylothorax. We report a case of spontaneous left-side chylothorax following septic pulmonary embolization (SPE) with Methicillin-Resistant Staphylococcus aureus (MRSA). This is a rare case of a nonmalignant, nontraumatic, and nontuberculous spontaneous chylothorax which was conservatively treated with fibrinolysis and diet modification. 1. Introduction with no mediastinal hilar adenopathy and no pleural effu- sion. There was no pulmonary artery filling defect or cardiac The accumulation of lymph in the pleural space due to dam- filling defect. We did not see any symptoms suggestive of age or obstruction of the thoracic duct results in chylothorax.
    [Show full text]
  • Diagnosis and Treatment of Pulmonary Arteriovenous Malformations In
    Diagnostic and Interventional Imaging (2013) 94, 835—848 REVIEW / Thoracic imaging Diagnosis and treatment of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: An overview ∗ P. Lacombe, A. Lacout , P.-Y. Marcy, S. Binsse, J. Sellier, M. Bensalah, T. Chinet, I. Bourgault-Villada, S. Blivet, J. Roume, G. Lesur, J.-H. Blondel, C. Fagnou, A. Ozanne, S. Chagnon, M. El Hajjam Radiology department, Pluridisciplinary HHT team, Ambroise-Paré Hospital, Groupement des Hôpitaux Île-de-France Ouest, Assistance Publique—Hôpitaux de Paris, Université de Versailles-Saint-Quentin-en-Yvelines, 9, avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France KEYWORDS Abstract Hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease is an Hereditary autosomic dominant disorder, which is characterized by the development of multiple arteriove- hemorrhagic nous malformations in either the skin, mucous membranes, and/or visceral organs. Pulmonary telangiectasia; arteriovenous malformations (PAVMs) may either rupture, and lead to life-threatening hemopt- Rendu-Osler disease; ysis/hemothorax or be responsible for a right-to-left shunting leading to paradoxical embolism, Pulmonary causing stroke or cerebral abscess. PAVMs patients should systematically be screened as the arteriovenous spontaneous complication rate is high, by reaching almost 50%. Neurological complications rate malformations; is considerably higher in patients presenting with diffuse pulmonary involvement. PAVM diagno- Percutaneous sis is mainly based upon transthoracic contrast echocardiography and CT scanner examination. embolization; The latter also allows the planification of treatments to adopt, which consists of percutaneous Right-to-left shunt embolization, having replaced surgery in most of the cases. The anchor technique consists of percutaneous coil embolization of the afferent pulmonary arteries of the PAVM, by firstly pla- cing a coil into a small afferent arterial branch closely upstream the PAVM.
    [Show full text]
  • Chronic Thromboembolic Pulmonary Hypertension Part 1
    American Thoracic Society PATIENT EDUCATION | INFORMATION SERIES Chronic Thromboembolic Pulmonary Hypertension Part 1 Normal blood vessel Chronic thromboembolic pulmonary Main pulmonary artery (blood flows freely) hypertension (CTEPH) is a condition Blood Vessel where there is elevated blood pressure in the pulmonary arteries caused by Left Right atrium CTEPH (blockage) chronic blood clots (thromboembolic), atrium Right Left which obstruct the free flow of blood ventricle ventricle through the lungs. This is a special form of pulmonary hypertension that, unlike the size of pulmonary vessels. These clots are called chronic all the other forms, can potentially be cured with a surgical thromboemboli, and are the cause of increased pulmonary procedure. This is why it is extremely important that your pressure. health care provider makes sure that chronic blood clots are not the cause of your pulmonary hypertension. What Causes Chronic Thromboembolic Pulmonary Hypertension? What Is Pulmonary Hypertension? The exact cause of CTEPH is not known. One or more episodes To understand chronic thromboembolic pulmonary of pulmonary embolism are the first step. Conditions that CLIP AND COPY AND CLIP hypertension, let’s start by briefly reviewing what pulmonary increase the chances of having blood clots include long periods hypertension (PH) is (see ATS Patient Series on PH at www. of inactivity, major surgical procedures, cancer, pregnancy thoracic.org/patients). After your blood has delivered oxygen to and the after pregnancy period, estrogen-containing oral the tissues of your body, the blood needs to come back to the contraceptives (birth control pills), obesity, and smoking, to lungs to get more oxygen. It does this by returning the blood name a few.
    [Show full text]